Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response
- 8 May 2020
- journal article
- review article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 86 (9) , 1736-1752
Abstract
Immune checkpoint blockade has transformed outcomes across solid organ tumours. Monoclonal antibodies targeting the negative inhibitory CTLA‐4 and PD‐1/PD‐L1 axis can lead to deep and durable responses across a number of tumour streams in the advanced setting. This immunotherapy approach is increasingly used earlier in the treatment paradigm. A rapidly evolving regulatory, reimbursement and drug development landscape has accompanied this novel class of immunotherapy. Unfortunately only a small proportion of patients respond meaningfully to these agents. Here we review how the underlying tumoral genomic, histologic and immunologic characteristics interact within various patient phenotypes, leading to variations in response to checkpoint blockade. Concurrently we outline the clinical trial and real world evidence that allows for appropriate selection of agent, dose and schedule in solid organ malignancies. An exploration of current trends in basic and translational research in immune checkpoint blockade accompanies a commentary on future clinical directions for checkpoint blockade in oncology.Keywords
This publication has 153 references indexed in Scilit:
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Endpoints for Cancer Immunotherapy TrialsJNCI: Journal of the National Cancer Institute, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responsesBritish Journal of Cancer, 2009
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 2009
- Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 AntibodyClinical Cancer Research, 2009
- PD-1 and Its Ligands in Tolerance and ImmunityAnnual Review of Immunology, 2008
- Anti‐angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte‐endothelium interactions and infiltration in tumorsThe FASEB Journal, 2006
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996